Feb. 13 at 2:54 PM
The biopharmaceutical company entered into an underwriting agreement with Piper Sandler & Co. for 10,815,000 ordinary shares priced at
$1.85 per share, according to a regulatory filing. The offering includes a 30-day option for the underwriter to purchase up to an additional 1,622,250 shares at the same price.
OKYO expects to generate approximately
$20 million in gross proceeds before underwriting discounts, commissions, and other expenses. The offering is scheduled to close on February 17, 2026, subject to customary closing conditions.
The company plans to use the net proceeds to advance the clinical development of its product candidates and for working capital and general corporate purposes. The shares are being offered under OKYO’s effective Form F-3 registration statement, declared effective by the SEC on February 10, 2026.
$OKYO